00:15 , Mar 2, 2018 |  BC Innovations  |  Product R&D

Sigma for synapses

By focusing on synapse protection instead of aggregate formation, Cognition Therapeutics Inc. has identified a new target for Alzheimer’s disease that it believes can block β amyloid’s toxic effects more efficiently than the standard approaches....
07:00 , Oct 24, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2; LIR2) ...
07:00 , Jun 14, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Leukemia Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2; LIR2) Mouse and cell culture studies suggest inhibiting...
08:00 , Dec 4, 2008 |  BC Innovations  |  Cover Story

New strategies for CNS regeneration

Two separate teams of company and university researchers have identified multiple neuronal proteins that could be targeted alone or in combination to promote axon growth and treat spinal cord injury and other forms of CNS...